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H I G H L I G H T S    
• PCSK9 plasma levels are higher in women than in men.  • The major determinants of PCSK9 levels are lipid-lowering therapies and latitude.  • Hypercholesterolemia and physical activity are independent predictors of PCSK9 only in men.  
A R T I C L E  I N F O   
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A B S T R A C T   
Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key regulators of low- 
density lipoprotein cholesterol plasma levels. Circulating PCSK9, which differs between genders, represents a 
valid pharmacological target for preventing cardiovascular (CV) events. We aimed to investigate sex-related 
associations between PCSK9 plasma levels and biochemical and anthropomorphic factors, and familial and 
personal morbidities, in a large European cohort (n = 3673) of men (47.9%) and women (52.1%). 
Methods: Individuals (aged 54–79 years) free of CV diseases were enrolled in seven centers of five European 
countries: Finland, France, Italy, the Netherlands, and Sweden. PCSK9 plasma levels were measured by ELISA. 
Results: PCSK9 was higher in women than in men. Multiple linear regression analysis showed that latitude, sex, 
and treatments with statins and fibrates were the strongest predictors of PCSK9 in the whole group. These 
variables, together with triglycerides and high-density lipoprotein cholesterol, were also associated with PCSK9 
in men or women. Mean corpuscular hemoglobin concentration and pack-years were PCSK9 independent pre-
dictors in women, whereas hypercholesterolemia and physical activity were independent predictors in men. The 
associations between PCSK9 and latitude, uric acid, diabetes, hypercholesterolemia and physical activity were 
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T
significantly different in men and women (pinteraction < 0.05 for all). 
Conclusions: Besides confirming the association with lipids in the whole group, our study revealed previously 
unknown differences in PCSK9 predictors in men and women. These might be taken into account when defining 
individual risk for CV events and/or for refining PCSK9 lowering treatments.   
1. Introduction 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble 
member of the mammalian proprotein convertase family of secretory 
serine endoproteases, mainly synthesized and secreted by the liver with 
a lower contribution of the intestine, kidney, brain, and other tissues 
[1]. 
PCSK9 post-transcriptionally regulates the levels of low-density li-
poprotein receptor (LDLR) by fostering its degradation [2]. By reg-
ulating hepatic LDLR, PCSK9 limits the LDL uptake maintaining high 
plasma levels of LDL-cholesterol (LDL-C) [3]. PCSK9 also mediates the 
inflammatory response [4] and is associated with the arterial plaques 
[5]. 
While PCSK9 represents the major regulator of LDL-C levels and, for 
this reason, an effective pharmacological target for preventing athero-
sclerotic cardiovascular (CV) diseases [6], the physiological predictors 
of its plasma concentrations still need to be elucidated. It is known that 
the synthesis of PCSK9 is dependent either on genetic polymorphisms 
[7], on transcriptional regulation by diverse nuclear factors [8], and on 
epigenetic mechanisms [9,10]. 
An important issue that needs further investigation is the role of sex. 
In the vast majority of CV diseases, there are differences between 
women and men in epidemiology, pathophysiology, clinical manifes-
tations, effects of therapy and outcomes [11]. On this matter, many 
studies in humans described PCSK9 plasma levels to be significantly 
higher in females than in males [7,12]. In addition, differences have 
been observed in postmenopausal compared to premenopausal women, 
as well as in pregnant compared to non-pregnant women, thus allowing 
to hypothesize a role of sex hormones in PCSK9 synthesis and/or me-
tabolism [7,13]. 
Considering the relevant role of PCSK9 on cholesterol homeostasis, 
on one hand, and the differences in CV risk factors [14] and in sub-
clinical atherosclerosis [15] between women and men, on the other, the 
aim of this cross-sectional cohort study was to investigate, in a large 
European cohort, the variables with a sex-specific association with 
PCSK9 plasma levels. 
2. Materials and methods 
2.1. Study subjects 
The database and the biobank of the IMPROVE study formed the 
basis of the present investigation. Such cohort consists of 3703 
Caucasian patients (1774 men, 1929 women, aged 54–79 years, with 
≥3 vascular risk factors) asymptomatic for cardio- and cerebrovascular 
diseases at the time of recruitment. Participants were enrolled in seven 
centers of five European countries: Finland (two centers), Sweden, the 
Netherlands, France, and Italy (two centers). Eligibility criteria for 
enrollment, objectives, methods, and patients’ baseline characteristics 
have been previously reported [16]. 
2.2. Smoking habits 
Subjects were carefully questioned about smoking habits, including 
duration of smoking calculated according to the year when smoking 
began (and ended, for former smokers) and average number of cigar-
ettes smoked per day. Patients were classified according to their 
smoking status as never, former, and current smokers. Never smokers 
were defined as those who had never smoked in their lifetime. Current 
smokers were defined as those who were smokers at enrolment and who 
had smoked at least 10 cigarettes/day for at least thirty months [17]. 
Former smokers were defined as those who had a pack-years ≥ 0.6 but 
had not smoked for at least 1 year before their interview. Pack-year 
(packs per day multiplied by number of years of smoke) was calculated 
for both current and former smokers. 
2.3. Ethical considerations 
The study complies with the rules of Good Clinical Practice and with 
the ethical principles established in the Helsinki Declaration, and was 
approved by local Ethics Committees in each study center. All patients 
gave written informed consent. 
2.4. Blood sampling and PCSK9 ELISA 
Venous blood samples were obtained after an overnight fast. Blood 
was maintained at 4 °C until the plasma was separated, aliquoted, and 
stored at −80 °C. Plasma PCSK9 concentrations were measured by a 
commercial ELISA kit (R&D Systems, MN) able to recognize free and 
LDLR-bound PCSK9. Plasma samples were diluted 1:20, according to 
the manufacturer's instructions, and incubated onto a microplate pre- 
coated with a monoclonal antibody specific for human PCSK9. Sample 
concentrations were obtained by generating a four-parameter logistic 
curve-fit. The minimum detectable concentration was 0.219 ng/mL. 
Intra- and inter-assay CVs were 5.4  ±  1.2% and 4.8  ±  1.0%, re-
spectively. 
2.5. Statistical analysis 
All quantitative variables were reported as mean  ±  SD. Variables 
with approximately log-normal distributions were presented as median 
and inter-quartile range (IQR), and log-transformed in parametric 
analyses. Although distribution was moderately skewed, PCSK9 levels 
were reported as mean  ±  SD, in order to allow comparisons with the 
existing literature. Categorical variables were reported as count and 
percentage. Trends across PCSK9 quintiles for continuous and catego-
rical variables were assessed by ANCOVA and Mantel-Haenszel χ2-test, 
respectively. All variables associated with PCSK9 plasma levels in 
univariate analysis with p  < 0.05 were screened as potential in-
dependent predictors and included in a multiple linear regression 
analysis with stepwise selection of variables. In this analysis, the p- 
value was corrected by the Bonferroni-Holm method, according to the 
number of variables entered. Relationships with a p-value lower than 
0.05 but higher than the Holm-Bonferroni threshold were considered 
not significant but suggestive of potential association. Covariance 
analysis (General Linear Models) was used to evaluate interactions 
between sex and each determinant of PCSK9 plasma levels after ad-
justing for confounders. Interaction tests were deemed as significant if 
the p-value was below 0.05, taking into account the reduced statistical 
power of this test. The proportion of PCSK9 variation accounted for 
each variable was evaluated by using multivariable partial correlations. 
A sensitivity analysis, aimed at evaluating whether pharmacological 
treatments modify the effects of predictors, was performed by excluding 
subjects treated with statins, fibrates or with a combination of both 
drugs from the original multivariable analysis. Analyses were carried 
out with the SAS statistical package v. 9.4 (SAS Institute Inc., Cary, NC, 
USA) and all tests were 2-sided. 
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3. Results 
Plasma PCSK9 was successfully measured in 3673 out of 3703 in-
dividuals included in the IMPROVE cohort [16]. PCSK9 measures 
showed a moderately right-skewed distribution with a mean con-
centration of 310.8  ±  108.6 ng/mL and a broad range, from 20.1 ng/ 
mL to 1133.9 ng/mL. 
The concentrations of PCSK9 were significantly higher 
(p  < 0.0001) in women than in men (331  ±  105 ng/mL vs 
290  ±  109 ng/mL) (Fig. 1) and were positively and significantly 
correlated with total cholesterol, LDL-C, high-density lipoprotein cho-
lesterol (HDL-C), and TG in the whole group (Fig. 2). 
Sex-specific baseline characteristics of this subsample, stratified by 
PCSK9 quintiles, are shown in Supplementary Table 1. 
3.1. Multiple regression analysis 
In a multivariable analysis including all variables significantly as-
sociated with PCSK9 in the univariate analysis (Supplementary 
Table 1), sex remained significantly associated with PCSK9 (Table 1). 
Moreover, considering the Holm-Bonferroni correction for multiple 
comparison, latitude, physical activity, and mean corpuscular hae-
moglobin concentration (MCHC) were negatively associated with 
PCSK9 in the entire cohort or in one of the two groups; pack-years, 
HDL-C, TG, personal history of hypercholesterolemia and treatments 
with statins and fibrates were instead positively associated. Suggestive 
associations with PCSK9 level were found for estimated glomerular 
filtration rate (GFR) (positive) and for family history of hypertension or 
diabetes (negative). 
The effects on plasma PCSK9 levels of latitude, physical activity, 
personal history of diabetes or hypercholesterolemia were different in 
men and women (pinteraction < 0.05 for all). As an example of such in-
teractions, Fig. 3 shows PCSK9 plasma levels according to latitude in 
men and women. The Beta values of changes in PCSK9 associated with a 
standard deviation increment of latitude were −0.334 in men and 
−0.224 in women (pinteraction < 0.0001). Personal history of diabetes 
and uric acid differently affected the plasma levels of PCSK9 in women 
and in men, even if their association was not significant in either group. 
The partial R2 obtained by multivariable partial correlations, which 
highlight the strength of the associations between PCSK9 and variables 
included in Table 1, are reported in Fig. 4. Notably, latitude and 
treatment with statins or fibrates were the strongest independent pre-
dictors of PCSK9, altogether accounting for 15% and 13% of PCSK9 
variation in women and men, respectively. 
Due to the strong associations of statins and fibrates with PCSK9 
levels, we ran a sensitivity analysis by excluding subjects treated with 
statins (40.1% of the total population), fibrates or a combination of 
both drugs from the multivariable analysis (Supplementary Tables 2, 3, 
and 4, respectively). The results clearly show that the exclusion of 
treated subjects did not substantially modify the β coefficients of all 
variables. 
4. Discussion 
Our study revealed unknown sex-specific predictors of PCSK9 
plasma levels. In particular, we found that MCHC and pack-years were 
independent predictors only in women. Conversely, unique in-
dependent predictors in men were personal history of hypercholester-
olemia and physical activity. A personal history of diabetes and uric 
acid had non-significant associations with PCSK9 in either gender, but 
the significant interactions indicated that their relations with PCSK9 are 
potentially different in the two genders. Common PCSK9 predictors in 
both sexes were latitude, HDL-C, TG, and treatments with statins or 
fibrates. These variables, together with sex, were the most significant 
predictors of PCSK9 plasma levels in the whole cohort. Interestingly, 
PCSK9 decreased with latitude in both men and women, but with a 
significant difference between the two groups (pinteraction < 0.0001). 
The present study is one of the largest analyses on PCSK9 plasma 
levels conducted in a European cohort (n = 3673). Two similarly large 
observational studies were performed by Lakoski et al. on the Dallas 
Heart Study (DHS) population (n = 3138) [7], and by Chernogubova 
et al. in 4 cohorts of healthy, middle-aged white (predominantly 
Swedish) subjects (n = 5722) [18]. Comparing our results with those of 
the DHS, a difference in the mean PCSK9 levels (i.e., 310.8 ng/mL vs 
517 ng/mL in the IMPROVE and DHS, respectively) clearly emerges. An 
analogous wide range variation in circulating PCSK9 levels (about 50- 
fold range) was found in the 4 cohorts included in the study by Cher-
nogubova et al. [18] . The use of different ELISA assays may account for 
this, considering the difference in the maximum plasma concentration 
detected in the IMPROVE and DHS studies (1133.9 ng/mL vs 2988 ng/ 
mL, respectively). A confirmation that between-study differences can be 
due to methodological issues (e.g., assays used or other confounders) is 
provided by the study of Leander et al. [19] and by the study of 
Chernogubova et al. [18], who documented mean levels of PCSK9 
(~100 ng/mL) much lower than those observed in the present study. 
Consistently, Ridker et al. in the Women's Health Study [20], and 
Gencer et al. in 2030 patients with acute coronary syndrome (ACS) [21] 
obtained comparable mean values of PCSK9 using the same commer-
cially available kit as in our study (302.1 ng/mL and 323 ng/mL, re-
spectively). 
Regardless of the absolute plasma concentrations of PCSK9, our 
findings are in line with most previous reports showing that PCSK9 
varies with sex, with the exception of two studies that find no gender 
difference in small cohorts [22,23]. Indeed, we found that PCSK9 
plasma concentration was higher in women than in men, in both the 
univariate and the multivariable analysis, and this result is in agree-
ment with studies in large, ethnically diverse, general populations 
[7,18,24], in a large population-based sample of children and adoles-
cents [25], and in diverse cohorts of patients with stable coronary ar-
tery disease (CAD) or ACS [26,27]. 
The main hypothesis of this work is that sex might affect the re-
lationship between PCSK9 and CV risk factors, of which a key factor is 
age. Plasma PCSK9 was found to be negatively correlated with age in 
adult and young males and positively in females [23,25]. In the present 
study, we observed a negative correlation between PCSK9 and age in 
both men and women at univariate analysis, which however lost its 
statistical significance when evaluated with a multivariable approach. 
Many studies assessed the relationship between PCSK9 levels and age 
and most of them found a positive correlation [28–30], one found no 
correlation even in univariate analysis [18], while only one found a 
negative correlation in human immunodeficiency virus-infected 
Fig. 1. Boxplot of plasma PCSK9 concentrations in the whole population, in 
women and in men. 
Differences between men and women were significant also after adjustment for 
age, total cholesterol, and triglycerides (p  < 0.0001). PCSK9, proprotein con-
vertase subtilisin/kexin type 9. 
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patients [31]. Among the studies that used a multivariate analytical 
approach, two confirmed the positive correlation with age in-
dependently of sex [30], whereas one found a positive correlation be-
tween PCSK9 levels and age only in women [29]. Overall, the PCSK9- 
age correlation appears to be scant and potentially influenced by other 
variables, including the oestrogen status of older vs younger women 
[29]. 
By computing interactions analyses, we found that the negative 
association between PCSK9 and personal history of diabetes is stronger 
in men than in women. Indeed, even if in our study the negative as-
sociation between PCSK9 and the personal history of diabetes was not 
significant in women and only "suggestive" in men, the significant in-
teraction observed indicates that the influence of sex is an additional 
layer of complexity in the interplay between PCSK9 and glucose me-
tabolism. This finding is in line with the observations that other risk 
factors for type 2 diabetes mellitus (T2DM) have a sexual dimorphism, 
such as the hepatokine fetuin A and 25(OH) vitamin D3, which were 
related to T2DM onset in women but not in men [32,33]. The “sug-
gestive” negative relationship with the personal history of diabetes 
observed in men is in line with large studies suggesting that loss-of- 
function PCSK9 genetic variants are associated with a higher risk of 
T2DM [34]. In addition, although baseline levels of PCSK9 did not 
predict the onset of diabetes in prediabetic patients, Ramin-Mangata 
et al. found a positive association with the change of fasting plasma 
glucose at a 4-year follow-up [35], suggesting that PCSK9 expression 
may be driven by insulin resistance, a common feature of the metabolic 
syndrome. Furthermore, the relationship between insulin resistance and 
PCSK9 levels may be affected by the dysbiosis of the gut microbiota 
which exacerbates insulin resistance, possibly leading to a rise in the 
expression of PCSK9 [36]. 
Another novel observation, stemming from computing the 
interaction effects, is that a personal history of hypercholesterolemia 
was positively associated with PCSK9 only in men. A positive associa-
tion was expected, since it has been reported that LDL-C and total 
cholesterol directly correlate with PCSK9 and that PCSK9 levels were 
higher in patients with familial hypercholesterolemia compared to 
control subjects [37]. Also in our analysis, total cholesterol and HDL-C 
were significantly correlated with PCSK9, as was LDL-C when excluding 
statins-treated patients. The Spearman correlation coefficients between 
PCSK9 and LDL-C were very similar in the IMPROVE study (ρ = 0.24) 
and in the DHS (ρ = 0.31). Hypercholesterolemia was one of the most 
important predictors of PCSK9 levels regardless of sex, but at the same 
time the association with a personal history of hypercholesterolemia, 
defined as LDL-C greater than 160 mg/dL, was restricted to men only. 
Further, we found a new negative predictor of PCSK9 levels, i.e. 
intensive physical activity in men. It is well known that supervised 
exercise therapy contributes to significantly lower LDL-C and total 
cholesterol levels [38], and thus the reduction of PCSK9 levels in re-
sponse to high physical activity may contribute to the final lipid-low-
ering effect. 
Latitude was one of the strongest independent predictors of PCSK9 
variation both in women and men. We also observed a significant in-
teraction with sex, being the decrease with increasing latitude greater 
in men than in women. A possible explanation of the negative asso-
ciation between PCSK9 and latitude, besides the well-known genetic 
gradient across Europe [39], could be the circadian variation of PCSK9. 
Indeed, during the day in healthy subjects PCSK9 levels have a nadir 
between 3 and 9 p.m. and a peak at 4:30 a.m. [40], and thus different 
light and dark cycles may affect PCSK9 synthesis. 
Regardless of biochemical and anthropomorphic factors, pharma-
cological treatments with statins and fibrates were the strongest pre-
dictors of PCSK9 variation. This effect was not new since the induction 
Fig. 2. Correlations between PCSK9 plasma levels and lipid parameters in the whole group. 
(A) Total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol; (D) triglycerides (log). For the analysis of LDL-cholesterol, statins users were excluded. PCSK9, 
proprotein convertase subtilisin/kexin type 9; LDL, low-density lipoproteins; HDL, high-density lipoproteins. 
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of PCSK9 by statins and fibrates is well known [41]; we confirmed this 
evidence in both men and women without any sex interaction. 
The relationship between PCSK9 and inflammation is still an object 
of intensive investigation. Indeed, while inflammation raises PCSK9 
liver expression and PCSK9 is positively linked to tumor necrosis factor- 
α [42], in the present study we found no relationship between PCSK9 
levels and high-sensitivity C-reactive protein, consistently with pre-
vious studies [20]. Our findings are also in line with the observation 
that PCSK9 antagonists do not exert a systemic anti-inflammatory ac-
tivity in treated patients [43]. On the contrary, a more intriguing 
finding is the correlation between plasma PCSK9 and platelet count. We 
have previously shown that PCSK9 added to platelet-rich plasma sam-
ples significantly enhanced platelet aggregation induced by a sub-
threshold concentration of epinephrine [24]. The absence of PCSK9 
reduced arterial thrombus formation and stability and platelet function 
in mice [24]. Taken together, these findings suggest a possible direct 
role of PCSK9 on platelets counts and aggregation, which are relevant 
factors not only in thrombus formation but also in the onset and pro-
gression of atherothrombotic disease [44]. 
A strong relationship between atherosclerosis and various factors 
linked to nutrition (obesity, blood sugar, saturated fat intake, micro-
biome, etc.) and smoking has been widely demonstrated [45]. On the 
other hand, several studies have related PCSK9 levels to obesity, insulin 
levels and certain dietary characteristics (high fat and protein intake, n- 
3 polyunsaturated fatty acids, etc.) [46] In our study, however, the 
univariate relationships with BMI, waist/hip ratio and blood glucose 
were not confirmed in the multivariate analysis, after correcting for 
gender, geographical origin and physical activity. 
Biomarkers of inflammation are the most sensitive to diet [47] and 
smoking intensity [48] even at the lowest dose of exposure, and this 
Fig. 3. PCSK9 plasma levels according to latitude. 
Geometric means were adjusted for therapies with statins or fibrates, triglycerides (log), personal history of hypercholesterolemia, physical activity, high-density 
lipoproteins cholesterol, and uric acid. PCSK9, proprotein convertase subtilisin/kexin type 9. 
Fig. 4. Strength of the associations be-
tween PCSK9 and predictors included 
in Table 1. 
Bars express the partial R2 of each 
predictor, i.e., the proportion of PCSK9 
variation explained by each variable in 
the multivariable analysis, for both 
women and men. PCSK9, proprotein 
convertase subtilisin/kexin type 9; 
P.H., personal history; HDL, high-den-
sity lipoproteins; F.H., family history; 
MCHC, mean corpuscular hemoglobin 
concentration; GFR, glomerular filtra-
tion rate. 
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relationship persists regardless of sex and race/ethnicity [48]. In our 
cohort, in a univariate analysis, we observed a positive association 
between pack-years and PCSK9 levels, both in men and women 
(Supplementary Table 1). Such relationship remained highly significant 
in the multivariate analysis, indeed pack-years was selected among the 
independent predictors of serum PCSK9. This finding may indicate a 
direct role of inflammatory mediators, induced by tobacco smoke, such 
as xanthine oxidoreductase [49], on PCSK9 levels [50]. 
4.1. Strengths and limitations 
The main strengths of the present study are related with the re-
markably large sample size (unique in this kind of studies), with the 
multicenter design, encompassing several European countries with 
different social and environmental characteristics, with the centralized 
measurement of PCSK9 and of most of the clinical variables, and with 
the standard of the data analysis, based on multivariable models con-
trolling for a wide array of factors. The study has also some potential 
limitations. The first arises from the peculiarity of the IMPROVE study 
population, including only subjects with multiple cardiovascular risk 
factors. The associations of PCSK9 levels with hypercholesterolemia, 
diabetes, treatment with statins and fibrates may be detectable only for 
this subpopulation. Therefore, the present results should be extra-
polated to the general population with great caution. Second, the po-
sitive association detected between PCSK9 and treatment with statins 
and fibrates may have been amplified by reverse causality. In fact, 
subjects at higher CV risk are more likely to have higher PCSK9 levels 
and to receive lipid-lowering treatment. However, the impact of this 
bias on our results is probably not substantial, because on one side the 
analyses were thoroughly corrected for many CV risk factors, and on the 
other the association of PCSK9 with lipid-lowering drugs has been 
widely documented in the literature. Third, the potential bias generated 
by unknown, unmeasured confounders and effect modifiers could not 
be addressed, although we carefully selected potential predictors of 
PCSK9 by running complex multivariable models and sensitivity ana-
lyses. A fourth limitation is the absence of a genetic analysis for the 
identification of PCSK9 mutations, although loss of function and par-
ticularly gain of function mutations are relatively rare in the Caucasian 
population [51]. Thus, the exclusion of these subjects from the analysis 
is predicted to have a minimal and not significant impact on the sta-
tistical results. Finally, this was a retrospective cohort study with a 
single determination of PCSK9 plasma levels and, thus, possible fluc-
tuations and different exposures to lipid-lowering drugs could not be 
considered. 
The clinical implications of the current findings are uncertain. 
Although evidence from this study clearly shows that PCSK9 is asso-
ciated with many independent markers and that some of these asso-
ciations (i.e. personal history of hypercholesterolemia and diabetes, uric 
acid and physical activity) are stronger in men than in women, whether 
such relationships are causal is still unknown. Clarifying the link be-
tween multiple risk factors and the blood level of PCSK9 and whether 
such link is different in men and women may, however, be important to 
help in understanding the characteristics of patients who may best 
benefit of specific treatments, including those with PCSK9 inhibitors, in 
a first step towards a “precision medicine”. 
4.2. Conclusions 
In our study, conducted on 3673 patients, we found several in-
dependent predictors of PCSK9 levels. Although some associations 
found were confirmatory, the novel finding of the present retrospective 
analysis is the influence of sex on the relationships between PCSK9 
plasma levels and several CV riskfactors and comorbidities. To our 
opinion, the observation that only in men PCSK9 levels are associated 
with pathological conditions, such as a personal history of diabetes or 
hypercholesterolemia, deserves a further investigation with prospective 
clinical studies. 
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